Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: A randomized, phase III study by the Danish breast cancer cooperative group Full Text
Journal of Clinical Oncology,  Clinical Article

Nielsen DL et al. – GD compared with docetaxel demonstrated increased TTP in metastatic breast cancer. RR and OS were similar. The addition of gemcitabine failed to demonstrate any clinically meaningful benefit when combined with docetaxel.

Methods

  • Predominantly human epidermal growth factor receptor 2 (HER2) –negative patients were randomly assigned to gemcitabine (1,000 mg/m2) on days 1 and 8 plus docetaxel (75 mg/m2) on day 8 or to docetaxel (100 mg/m2) on day 1, every 21 days
  • Patients were untreated or had prior (neo)adjuvant chemotherapy or a single anthracycline-based chemotherapy regimen for metastatic breast cancer
  • Primary end point was time to progression (TTP), and secondary end points were OS, response rate (RR), and toxicity

Results
  • 170 patients were allocated to GD, and 167 were allocated to docetaxel
  • Median TTP on GD was 10.3 months versus 8.3 months on docetaxel (HR, 0.77; 95% CI, 0.59 to 1.01; log-rank P = .06)
  • Adjusted Cox proportional model for TTP showed significant difference favoring combination (HR, 0.68; 95% CI, 0.51 to 0.90; P = .007)
  • RR was similar (GD, 36%; docetaxel, 34%), and OS was not different (P = .57)
  • Grades 3 to 4 neutropenia was common (GD, 75%; docetaxel, 69%); infection was reported in 26% and 21% of patients in the GD and docetaxel groups, respectively
  • Grades 3 to 4 thrombocytopenia was more frequent with GD (GD, 16%; docetaxel, 0.6%), and peripheral neuropathy was higher with docetaxel (GD, 5%; docetaxel, 16%)

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer European Journal of Cancer, August 6, 2014    Clinical Article

2 Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response The Lancet Oncology, August 19, 2014    Clinical Article

3 Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies Breast Cancer Research and Treatment, August 1, 2014    Evidence Based Medicine    Review Article

4 Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany The Breast, July 24, 2014

5 Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer International Journal of Cancer, August 11, 2014    Clinical Article

6 A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia British Journal of Haematology, August 11, 2014    Clinical Article

7 Observation after a positive sentinel lymph node biopsy in patients with melanoma Annals of Surgical Oncology, August 20, 2014    Clinical Article

8 Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study Journal of Clinical Oncology, July 17, 2014

9 Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: A population-based analysis Full Text BMC Cancer, August 21, 2014    Free full text    Clinical Article

10 A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study Journal of Cancer Research & Clinical Oncology, August 29, 2014    Clinical Article

11 Screening for prostate cancer in the US? Reduce the harms and keep the benefit International Journal of Cancer, August 15, 2014    Clinical Article

12 Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: A North Central Cancer Treatment Group study, N0675 American Journal of Clinical Oncology, August 14, 2014    Clinical Article

13 Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer Breast Cancer Research and Treatment, August 4, 2014    Clinical Article

14 FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial The Lancet Oncology, August 4, 2014    Clinical Article

15 Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: The Cancer Prevention Study-II Nutrition Cohort Journal of Clinical Oncology, July 9, 2014    Clinical Article

16 Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology, March 7, 2014    Clinical Article

17 Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR Breast Cancer Research and Treatment, August 12, 2014    Clinical Article

18 Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012 empirical relationships JAMA Dermatology, August 13, 2014    Review Article

19 Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells Cancer, July 2, 2014    Clinical Article

20 Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma Full Text BMC Cancer, August 1, 2014    Free full text

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close